JPH08310923A - Testosterone 5alpha-reductase inhibitor - Google Patents
Testosterone 5alpha-reductase inhibitorInfo
- Publication number
- JPH08310923A JPH08310923A JP7144149A JP14414995A JPH08310923A JP H08310923 A JPH08310923 A JP H08310923A JP 7144149 A JP7144149 A JP 7144149A JP 14414995 A JP14414995 A JP 14414995A JP H08310923 A JPH08310923 A JP H08310923A
- Authority
- JP
- Japan
- Prior art keywords
- essential oil
- leaves
- testosterone
- reductase inhibitor
- flowers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
【0001】[0001]
【産業上の利用分野】本発明は、男性ホルモンが関与す
る種々の疾患の治療および予防に有効なテストステロン
5α-リダクターゼ阻害剤に関するものである。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a testosterone 5α-reductase inhibitor which is effective in treating and preventing various diseases involving androgen.
【0002】[0002]
【従来の技術】男性型禿症、脱毛症、多毛症、皮脂分泌
機能の亢進が原因とされる痙瘡や脂漏、アポクリン腺の
機能障害で起きる化膿性汗腺炎等は、男性ホルモンであ
るテストステロンが発症原因または増悪因子になること
によるものと考えられている。すなわち、男性生殖器に
付属する器官から分泌された男性ホルモン・テストステ
ロンが血流により標的器官に運ばれて選択的に取り込ま
れた後、細胞内のテストステロン5α-リダクターゼに
より活性の高いジヒドロキシテストステロンに変換さ
れ、これが細胞内の受容体と結合し、核に作用して、毛
母細胞では細胞分裂を抑制して毛の成長を妨げ、皮脂腺
細胞に対しては増殖を促すという作用機構が考えられて
いる。2. Description of the Related Art Male pattern baldness, alopecia, hirsutism, acne and seborrhea caused by hypersecretion of sebum, and purulent sweating gland inflammation caused by dysfunction of apocrine gland are male hormones. It is thought that testosterone is the cause of onset or an exacerbation factor. That is, the male hormone testosterone secreted from the organs attached to the male reproductive organs is transported to the target organ by the bloodstream and selectively taken up, and then converted into highly active dihydroxytestosterone by intracellular testosterone 5α-reductase. , It is thought that the mechanism of action is that it binds to intracellular receptors, acts on the nucleus, suppresses cell division in hair mother cells, prevents hair growth, and promotes proliferation in sebaceous gland cells. .
【0003】そこで、テストステロンが関与する各種疾
患の治療にはテストステロン5α-リダクターゼの作用
を阻害する物質や抗男性ホルモン作用を有する物質が使
われまたは提案されている。Therefore, for the treatment of various diseases related to testosterone, a substance that inhibits the action of testosterone 5α-reductase or a substance having an antiandrogen action has been used or proposed.
【0004】しかしながら、従来テストステロン5α-
リダクターゼ阻害剤として提案された物質は、いずれも
効果が不十分であったり安全性に問題があったりしたた
め、広く一般的に使われることはなかった。また、オキ
センドロン、酢酸ジプロテロン、酢酸クロルヤジノン
等、従来の抗男性ホルモン剤は、いずれもステロイド剤
であって、生体に長期間投与すると副作用を示すことが
多く、安全性の面で問題があった。However, conventional testosterone 5α-
The substances proposed as reductase inhibitors have not been widely and generally used because of their insufficient effects and safety problems. Further, conventional anti-androgen agents such as oxendron, diproterone acetate, chloryadinone acetate, etc. are all steroid agents, and often have side effects when administered to a living body for a long time, which is a problem in terms of safety.
【0005】[0005]
【発明が解決しようとする課題】本発明の目的は、安全
性に問題の多いステロイド剤に依存することなく上記ジ
ヒドロキシテストステロンに起因する疾患の治療と予防
を可能にする手段を提供することにある。SUMMARY OF THE INVENTION An object of the present invention is to provide means for enabling the treatment and prevention of the above-mentioned diseases caused by dihydroxytestosterone without depending on the steroid drug which has a problem of safety. .
【0006】[0006]
【課題を解決するための手段】本発明は、安全性の高い
新規テストステロン5α-リダクターゼ阻害剤、すなわ
ちオレンジ(Citrus aurantium L.)の果皮、セージ
(Salvia officinalisL.)の葉および花、ペパーミ
ント(Mentha piperita L.)の葉、ユーカリ(Euca
lyptus globulus L.)の葉、ヨモギ(Artemisia prin
ceps P.およびArtemisia mongolia F.)の葉、ラベ
ンダー(Lavandula vera D.C.)の花、ローズ(Rosa
centifolia L.)の花、およびローズマリー(Rosmari
nus off-icinalis L.)の葉よりなる群から選ばれた植
物体より水蒸気蒸留により得られた精油を有効成分とし
て含有することを特徴とするテストステロン5α-リダ
クターゼ阻害剤を提供するものである。The present invention provides a highly safe novel testosterone 5α-reductase inhibitor, namely, orange (Citrus aurantium L.) pericarp, sage (Salvia officinalis L.) leaves and flowers, peppermint (Mentha). piperita L. leaves, Eucalyptus (Euca)
lyptus globulus L. leaf, mugwort (Artemisia prin)
ceps P.P. And Artemisia mongolia F.) leaves, lavender (Lavandula vera DC) flowers, rose (Rosa)
centifolia L. flower and rosemary (Rosmari)
(Nus off-icinalis L.) leaves, which contain as an active ingredient an essential oil obtained by steam distillation from a plant selected from the group consisting of leaves.
【0007】上述の精油はいずれも市販されており、本
発明にはそれをそのまま使用することができるが、原料
植物体から水蒸気蒸留の常法により製造することもでき
る。すなわち、原料植物体の堆積層に水蒸気を連続的に
供給してその植物体を加熱状態にし、加熱された植物体
堆積層通過後の水蒸気を冷却器で冷却して凝縮液を採取
し、それを静置すると分離する油層を採取する。精油の
一部は水層にも分散もしくは溶解しているので、有機溶
剤抽出により回収して利用してもよい。All of the above-mentioned essential oils are commercially available and can be used as they are in the present invention, but they can also be produced from a raw material plant by a conventional method of steam distillation. That is, the steam is continuously supplied to the sedimentary layer of the raw material plant to bring the plant into a heated state, and the steam after passing the heated plant sedimentary layer is cooled by a cooler to collect a condensate, which Collect the oil layer that separates when left to stand. Since a part of the essential oil is also dispersed or dissolved in the aqueous layer, it may be recovered by organic solvent extraction and used.
【0008】上記特定の植物体より水蒸気蒸留により得
られる精油は優れたテストステロン5α-リダクターゼ
阻害作用を示す。この酵素阻害作用は次のような試験に
より確認された。The essential oil obtained from the above specific plant by steam distillation shows an excellent testosterone 5α-reductase inhibitory action. This enzyme inhibitory action was confirmed by the following tests.
【0009】試験方法:テストステロン(東京化成株式
会社)4.2mgをプロピレングリコール1mlに溶解し、
その20μlにNADPH(ORIENTAL YEAST)を濃度1m
g/mlに溶解した5mMトリス塩酸緩衝液(pH7.2)8
25μlを加える。これに試料溶液(精油をエタノール
に溶解した溶液)80μlおよびS-9(ラット肝ホモジ
ネート;ORIENTAL YEAST)75μlを加え、37℃で3
0分間インキュベーションする。次いで塩化メチレン1
mlを加えて反応を停止し、塩化メチレン層を分取して、
反応生成物であるジヒドロキシテストステロン、アンド
ロスタンジオール等をガスクロマトグラフィーにより定
量する。試料精油無添加時の反応生成物量に対する精油
添加時の反応生成物量の比率より、テストステロン5α
-リダクターゼ阻害率を求める。Test method: Dissolve 4.2 mg of testosterone (Tokyo Kasei Co., Ltd.) in 1 ml of propylene glycol,
NADPH (ORIENTAL YEAST) was added to 20 μl to a concentration of 1 m.
5 mM Tris-HCl buffer (pH 7.2) 8 dissolved in g / ml
Add 25 μl. To this, 80 μl of sample solution (solution of essential oil in ethanol) and 75 μl of S-9 (rat liver homogenate; ORIENTAL YEAST) were added, and the mixture was mixed at 37 ° C. for 3 days.
Incubate for 0 minutes. Then methylene chloride 1
The reaction was stopped by adding ml, and the methylene chloride layer was separated,
The reaction products such as dihydroxytestosterone and androstanediol are quantified by gas chromatography. From the ratio of the amount of reaction product when the essential oil was added to the amount of reaction product when the sample essential oil was not added, testosterone 5α
-Determine the reductase inhibition rate.
【0020】上記方法において、反応液中の精油濃度を
種々変更してテストステロン5α-リダクターゼ阻害率
を求め、その結果から内挿法により、酵素活性を50%
阻害する精油濃度を求める。In the above method, the concentration of essential oil in the reaction solution was variously changed to obtain the testosterone 5α-reductase inhibitory rate, and the enzyme activity was determined to be 50% by interpolation from the results.
Determine the essential oil concentration to inhibit.
【0021】なお、酵素阻害作用が酵素の蛋白を変性す
ることによるものでないことを確認するため、蛋白変性
試験を併せて行なった。試験は、胎児血清アルブミン
(Fr.V:SIGMA)を0.02%溶解したリン酸緩
衝液(pH6.8)9mlに試料溶液1mlを加え、10分間
撹拌後、メンブランフィルターで濾過し、液体クロマト
グラフィーによりアルブミンを定量する方法により行な
った(注:反応液における精油濃度50ppm)。試験結
果を表1に示す。A protein denaturation test was also conducted in order to confirm that the enzyme inhibitory action was not due to denaturation of the protein of the enzyme. The test was carried out by adding 1 ml of the sample solution to 9 ml of phosphate buffer (pH 6.8) containing 0.02% of fetal serum albumin (Fr.V: SIGMA), stirring for 10 minutes, filtering with a membrane filter, and liquid chromatography. It was carried out by a method of quantifying albumin by chromatography (Note: the concentration of essential oil in the reaction solution was 50 ppm). Table 1 shows the test results.
【0022】[0022]
【表1】 試 料 50%阻害濃度(ppm) 蛋白変性率(%) オレンジ精油 15 17.0 セージ精油 >2000 0.1 ペパーミント精油 22 0.9 ユーカリ精油 50 0.6 ヨモギ精油 22 2.1 ラベンダー精油 18 4.3 ローズ精油 17 0.8 ローズマリー精油 2000 0.1TABLE 1 specimen 50% inhibitory concentration (ppm) protein modification ratio (%) Orange essential oil 15 17.0 sage essential oil> 2000 0.1 Peppermint essential oil 22 0.9 Eucalyptus essential oil 50 0.6 Artemisia essential oil 22 2.1 Lavender essential oil 18 4.3 Rose essential oil 17 0.8 Rosemary essential oil 2000 0.1
【0023】表1から明らかなように、オレンジ精油、
ペパーミント精油、ユーカリ精油、ヨモギ精油、ラベン
ダー精油およびローズ精油は非常に高いテストステロン
5α-リダクターゼ阻害活性を示した。セージ精油およ
びローズマリー精油は比較的高い濃度で活性を示した。
蛋白変性作用はオレンジ精油に若干あったほかはほとん
ど認められなかった。オレンジ精油の蛋白変性作用も、
この精油の強い活性からみて、測定される酵素阻害率の
ごく一部に関係しているに過ぎないものと推察される。As is clear from Table 1, orange essential oil,
Peppermint essential oil, eucalyptus essential oil, mugwort essential oil, lavender essential oil and rose essential oil showed very high testosterone 5α-reductase inhibitory activity. Sage essential oil and rosemary essential oil were active at relatively high concentrations.
The protein denaturing effect was hardly observed except for some orange essential oil. The protein denaturing action of orange essential oil,
Given the strong activity of this essential oil, it is speculated that it is only related to a small portion of the enzyme inhibition rate measured.
【0024】本発明によるテストステロン5α-リダク
ターゼ阻害剤は、男性ホルモンの作用が発症原因あるい
は増悪因子である種々の疾患、たとえば男性型脱毛症、
多毛症、皮脂分泌機能亢進に伴なう脂漏や痙瘡、化膿性
汗腺炎、腋臭等の予防および治療に外用剤として使用す
ることができる。The testosterone 5α-reductase inhibitor according to the present invention is used in various diseases, such as androgenetic alopecia, in which the action of androgen is the cause or aggravation factor.
It can be used as an external preparation for the prevention and treatment of hirsutism, seborrhea and acne associated with hypersecretion of sebum, suppurative sweat gland inflammation, axillary odor, and the like.
【0025】本発明のテストステロン5α-リダクター
ゼ阻害剤は、軟膏、ローション、乳液、トニック、スプ
レー、懸濁液、溶液剤等、外用に適した剤形を任意に採
用することができる。製剤化に際しては、有効成分であ
る精油以外に、エタノールのような低級アルコール、セ
タノールのような高級アルコール、プロピレングリコー
ルのような多価アルコール、ヒドロキシプロピルセルロ
ースのような水溶性セルロース誘導体、各種油脂成分、
ワセリン、ロウ、シリコーン、界面活性剤、酸化亜鉛等
の希釈剤、懸濁剤、芳香剤、保湿剤、防腐剤等の補助剤
を適宜配合することができる。これらの製剤における精
油の含有率は、約0.01〜1重量%程度が適当であ
る。The testosterone 5α-reductase inhibitor of the present invention may be in any form suitable for external use, such as an ointment, lotion, emulsion, tonic, spray, suspension or solution. In formulating, in addition to the essential oil as an active ingredient, lower alcohols such as ethanol, higher alcohols such as cetanol, polyhydric alcohols such as propylene glycol, water-soluble cellulose derivatives such as hydroxypropyl cellulose, various oil and fat components. ,
An auxiliary agent such as a petrolatum, a wax, a silicone, a surfactant, a diluent such as a zinc oxide, a suspending agent, an aromatic agent, a moisturizing agent, and a preservative can be appropriately added. The appropriate content of essential oil in these preparations is about 0.01 to 1% by weight.
【0026】有効成分である精油が皮膚に何らかの好ま
しくない炎症を誘発することは、上記好適配合量の範囲
ではほとんどない。The essential oil, which is the active ingredient, induces some undesired inflammation on the skin in the range of the above preferable compounding amount.
【0027】本発明のテストステロン5α-リダクター
ゼ阻害剤は、上記用途に単独で使用するほか、他の任意
の皮膚外用剤または化粧料に配合しておき、それらの使
用に伴ない皮膚に適用されるようにしてもよい。The testosterone 5α-reductase inhibitor of the present invention is used alone in the above-mentioned applications, and is also compounded with any other external preparation for skin or cosmetics and applied to the skin in accordance with their use. You may do it.
【0028】[0028]
実施例1 精油の0.05重量%エタノール溶液からなる本発明テ
ストステロン5α-リダクターゼ阻害剤を調製し、その
皮脂分泌抑制作用を次の方法で試験した。試験方法:本
発明阻害剤で湿潤させた脱脂綿(4cm2)を健常人の前
額部の左側部に、また対照液(エタノール)を湿潤させ
た脱脂綿を同じ被験者の前額部右側部に、それぞれ絆創
膏で固定する。8時間経過後、脱脂綿を取り外し、脱脂
綿を当てておいた部位で分泌されて脱脂綿に吸収された
皮脂をエタノールで抽出する。得られた抽出物につい
て、分泌された皮脂の主成分であるスクワレンをガスク
ロマトグラフィーで定量し、対照液使用部位におけるス
クワレン分泌量に対する本発明阻害剤使用部位における
スクワレン分泌量の比率より皮脂分泌抑制率を求める。
20名の被験者について行なった試験結果を表2に示
す。Example 1 A testosterone 5α-reductase inhibitor of the present invention comprising an essential oil in a 0.05% by weight ethanol solution was prepared, and its sebum secretion inhibitory effect was tested by the following method. Test method: Absorbent cotton (4 cm 2 ) moistened with the inhibitor of the present invention was applied to the left side of the forehead of a healthy person, and absorbent cotton moistened with the control solution (ethanol) was applied to the right side of the forehead of the same subject. Fix each with a bandage. After the lapse of 8 hours, the absorbent cotton is removed, and the sebum secreted at the part to which the absorbent cotton is applied and absorbed by the absorbent cotton is extracted with ethanol. For the obtained extract, squalene, which is the main component of secreted sebum, was quantified by gas chromatography, and sebum secretion was suppressed from the ratio of the squalene secretion amount of the inhibitor of the present invention to the squalene secretion amount of the control liquid use site. Find the rate.
Table 2 shows the results of the tests conducted on 20 test subjects.
【0029】 [0029]
【表2】 スクワレン分泌量(平均値;mg/4cm2) 試 料 本発明品使用部位 対照液使用部位 皮脂分泌抑制率(%) オレンジ精油 0.112 0.168 33.3 セージ精油 0.170 0.186 8.6 ペパーミント精油 0.150 0.200 25.0 ユーカリ精油 0.150 0.174 13.8 ヨモギ精油 0.134 0.186 28.0 ラベンダー精油 0.114 0.162 29.6 ローズ精油 0.134 0.184 27.2 ローズマリー精油 0.154 0.162 4.9 [Table 2] Squalene secretion amount (average value; mg / 4cm 2 ) Reagent Site of the present invention Control site of control solution Sebum secretion suppression rate (%) Orange essential oil 0.112 0.168 33.3 Sage essential oil 0.170 0.186 8.6 peppermint essential oil 0.150 0.200 25.0 eucalyptus essential oil 0.150 0.174 13.8 mugwort essential oil 0.134 0.186 28.0 lavender essential oil 0.114 0.162 29.6 Rose essential oil 0.134 0.184 27.2 Rosemary essential oil 0.154 0.162 4.9
【0030】実施例2 50%エタノールにラベンダー精油を濃度が0.05%
になるように溶解して本発明のテストステロン5α-リ
ダクターゼ阻害剤を調製した。Example 2 Lavender essential oil was added to 50% ethanol at a concentration of 0.05%.
The testosterone 5α-reductase inhibitor of the present invention was prepared by dissolving.
【0031】男性型脱毛症および頭部脂漏性皮膚炎の症
状を有する25歳から35歳までの男性9名に上記阻害
剤を、通常使用しているヘアトニックに替えて2カ月
間、朝夕各1回、頭部に散布させた。Nine males aged 25 to 35 with androgenetic alopecia and seborrheic dermatitis symptoms were substituted with the above-mentioned inhibitor for the usual hair tonic for two months, morning and evening. It was sprayed on the head once each time.
【0032】上記試用試験の開始日と終了日に、被験者
に同一条件で洗髪をさせ、そのときの脱毛本数を測定し
た。その結果は表3のとおりであって、本発明のテスト
ステロン5α-リダクターゼ阻害剤が脱毛量を減少させ
る効果が確認された。On the start and end dates of the trial test, the test subjects were made to wash their hair under the same conditions, and the number of hair loss at that time was measured. The results are shown in Table 3, and it was confirmed that the testosterone 5α-reductase inhibitor of the present invention has an effect of reducing the amount of hair loss.
【0033】[0033]
【表3】 脱毛本数(本)被験者 試験開始時 試験終了時 A 115 81 B 78 50 C 103 45 D 110 75 E 95 39 F 78 38 G 92 52 H 49 32 I 74 41[Table 3] Number of Hair Loss (Number) Subject Test Start At Test End A 115 81 B 78 50 C 103 45 D 110 75 E 95 39 F 78 38 G 92 52 H 49 32 I 74 41
【0034】実施例3 50%エタノールにセージ精油およびローズマリー精油
を濃度がいずれも0.05%になるように溶解して本発
明のテストステロン5α-リダクターゼ阻害剤を調製し
た。Example 3 A testosterone 5α-reductase inhibitor of the present invention was prepared by dissolving sage essential oil and rosemary essential oil in 50% ethanol to a concentration of 0.05%.
【0035】男性型脱毛症および頭部脂漏性皮膚炎の症
状を有する25歳から35歳までの男性8名に対し、上
記阻害剤の効果を、実施例2の場合と同様にして確認し
た。その結果は表4のとおりであって、本発明のテスト
ステロン5α-リダクターゼ阻害剤が脱毛量を減少させ
る効果が確認された。The effect of the above inhibitor was confirmed in the same manner as in Example 2 on 8 males aged 25 to 35 having androgenetic alopecia and seborrheic dermatitis symptoms. . The results are shown in Table 4, and it was confirmed that the testosterone 5α-reductase inhibitor of the present invention has an effect of reducing the amount of hair loss.
【0036】[0036]
【表4】 脱毛本数(本)被験者 試験開始時 試験終了時 A 88 72 B 106 72 C 77 45 D 131 75 E 102 39 F 101 38 G 83 52 H 94 32[Table 4] Number of hair loss (lines) Subject test Start of test End of test A 88 72 B 106 72 C 77 45 D 131 75 E E 102 39 F 101 38 G 83 52 H 94 32
【0037】使用例1(トニックに配合した例) ペパーミント精油 0.05g 塩酸ピリドキシン 0.1g レゾルシン 0.01g D-パントテニルアルコール 0.1g グリチルリチン酸ジカリウム 0.1g ニンジン抽出エキス 0.5g メントール 0.05g 1,3-ブチレングリコール 5.0g エタノール 15.0g 蒸留水 79.09gUse Example 1 (Example of blending in tonic) Peppermint essential oil 0.05 g Pyridoxine hydrochloride 0.1 g Resorcin 0.01 g D-pantothenyl alcohol 0.1 g Dipotassium glycyrrhizinate 0.1 g Carrot extract extract 0.5 g Menthol 0.1 05g 1,3-butylene glycol 5.0g ethanol 15.0g distilled water 79.09g
【0038】使用例2(ローションに配合した例) ヨモギ精油 0.05g グリチルリチン酸ジカリウム 0.2g 1,3-ブチレングリコール 4.0g オレイルアルコール 4.0g POE・ソルビタンモノラウレート(20EO) 1.5g POE・ラウリルエーテル(20EO) 0.5g エタノール 15.0g パラヒドロキシ安息香酸メチル 0.05g パラヒドロキシ安息香酸エチル 0.05g (蒸留水を加えて全量を100.0gとする。)Use Example 2 (example mixed in lotion) Wormwood essential oil 0.05 g Dipotassium glycyrrhizinate 0.2 g 1,3-butylene glycol 4.0 g Oleyl alcohol 4.0 g POE sorbitan monolaurate (20EO) 1.5 g POE lauryl ether (20EO) 0.5 g Ethanol 15.0 g Methyl parahydroxybenzoate 0.05 g Ethyl parahydroxybenzoate 0.05 g (Add distilled water to make the total amount 100.0 g)
【0039】使用例3(クリームに配合した例) ペパーミント精油 0.01g オレンジ精油 0.01g ステアリルグリチルレチネート 0.1g ビーズワックス 10.0g セタノール 5.0g 親水ラノリン 8.0g スクワラン 37.5g グリセリルモノステアレート 2.0g POE・ソルビタンモノラウレート(20EO) 2.5g ポリエチレングリコール 5.0g パラヒドロキシ安息香酸メチル 0.05g パラヒドロキシ安息香酸エチル 0.05g (蒸留水を加えて全量を100.0gとする。)Use Example 3 (Example of Compounding in Cream) Peppermint Essential Oil 0.01 g Orange Essential Oil 0.01 g Stearyl Glycyrrhetinate 0.1 g Beeswax 10.0 g Cetanol 5.0 g Hydrophilic Lanolin 8.0 g Squalane 37.5 g Glyceryl Monostearate 2.0g POE / sorbitan monolaurate (20EO) 2.5g Polyethylene glycol 5.0g Methyl parahydroxybenzoate 0.05g Ethyl parahydroxybenzoate 0.05g (total amount is 100.0g by adding distilled water) And)
【0040】[0040]
【発明の効果】本発明のテストステロン5α-リダクタ
ーゼ阻害剤の構成成分は古くからハーブや生薬として利
用されてきた植物体から採取される精油であり、安全性
が確認されているものである。したがって、本発明によ
り安全性に問題のあるステロイド剤に依存する必要がな
くなり、ジヒドロキシテストステロンに起因する各種疾
患の治療と予防を従来よりも容易に行うことが可能にな
る。The constituents of the testosterone 5α-reductase inhibitor of the present invention are essential oils collected from plants that have been used as herbs and crude drugs for a long time, and their safety has been confirmed. Therefore, according to the present invention, it is not necessary to depend on a steroid drug having a safety problem, and treatment and prevention of various diseases caused by dihydroxytestosterone can be performed more easily than before.
Claims (1)
皮、セージ(Salviaofficinalis L.)の葉および花、
ペパーミント(Mentha piperita L.)の葉、ユーカリ
(Eucalyptus globulus L.)の葉、ヨモギ(Artemisi
a princeps P.およびArtemisia mongolia F.)の葉、
ラベンダー(Lavandula vera D.C.)の花、ローズ(R
osa centifolia L.)の花、およびローズマリー(Ros
marinusofficinalis L.)の葉よりなる群から選ばれた
植物体より水蒸気蒸留により得られた精油を有効成分と
して含有することを特徴とするテストステロン5α-リ
ダクターゼ阻害剤。1. An orange (Citrus aurantium L.) pericarp, sage (Salvia officinalis L.) leaves and flowers,
Leaves of peppermint (Mentha piperita L.), leaves of eucalyptus (Eucalyptus globulus L.), mugwort (Artemisi)
a princeps P. And Artemisia mongolia F.) leaves,
Lavender (Lavandula vera DC) flower, rose (R
osa centifolia L. ) Flowers and rosemary (Ros
marinusofficinalis L.) A testosterone 5α-reductase inhibitor, which contains, as an active ingredient, an essential oil obtained by steam distillation from a plant selected from the group consisting of leaves.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP7144149A JPH08310923A (en) | 1995-05-19 | 1995-05-19 | Testosterone 5alpha-reductase inhibitor |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP7144149A JPH08310923A (en) | 1995-05-19 | 1995-05-19 | Testosterone 5alpha-reductase inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH08310923A true JPH08310923A (en) | 1996-11-26 |
Family
ID=15355362
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP7144149A Pending JPH08310923A (en) | 1995-05-19 | 1995-05-19 | Testosterone 5alpha-reductase inhibitor |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH08310923A (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2771288A1 (en) * | 1997-11-03 | 1999-05-28 | Da Min Enterprise Ltd | HAIR TREATMENT COMPOSITION AND MANUFACTURING METHOD THEREOF |
JP2001226278A (en) * | 2000-02-15 | 2001-08-21 | Maruzen Pharmaceut Co Ltd | Antiandrogen agent |
JP2002020242A (en) * | 2000-07-06 | 2002-01-23 | Lion Corp | Hair care preparation composition |
JP2003081802A (en) * | 2001-09-14 | 2003-03-19 | Kose Corp | Masking agent and cosmetic comprising the same |
KR100401456B1 (en) * | 1999-12-24 | 2003-10-11 | (주) 한국신과학 기술센타 | Pharmaceutical composition comprising pectin effective in inhibiting the male reproductive toxicity |
US6638523B1 (en) | 1999-10-27 | 2003-10-28 | Nagase & Company, Ltd. | Method of treating ulcers |
KR20040016546A (en) * | 2002-08-17 | 2004-02-25 | 고운맘 | How to prepare wormwood oil |
JP2005035903A (en) * | 2003-07-16 | 2005-02-10 | Lion Corp | Hair-restoring and growing agent composition |
KR100521783B1 (en) * | 2002-07-23 | 2005-10-14 | 주식회사 내츄로바이오텍 | Composition containing extract derived from natural products that have growth-inhibition activity against dandruff causing microorganism |
KR100521782B1 (en) * | 2002-07-23 | 2005-10-14 | 주식회사 내츄로바이오텍 | Composition containing extract derived from natural products that have growth-inhibition activity against dandruff causing microorganism |
JP2013028572A (en) * | 2011-07-29 | 2013-02-07 | Unitika Ltd | Sebum production inhibitor |
JP2013530214A (en) * | 2010-07-01 | 2013-07-25 | ユン コ、ド | Method for producing composition for improving hair and scalp condition in which efficacy of blended aroma oil is enhanced |
-
1995
- 1995-05-19 JP JP7144149A patent/JPH08310923A/en active Pending
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2771288A1 (en) * | 1997-11-03 | 1999-05-28 | Da Min Enterprise Ltd | HAIR TREATMENT COMPOSITION AND MANUFACTURING METHOD THEREOF |
US6638523B1 (en) | 1999-10-27 | 2003-10-28 | Nagase & Company, Ltd. | Method of treating ulcers |
KR100401456B1 (en) * | 1999-12-24 | 2003-10-11 | (주) 한국신과학 기술센타 | Pharmaceutical composition comprising pectin effective in inhibiting the male reproductive toxicity |
JP2001226278A (en) * | 2000-02-15 | 2001-08-21 | Maruzen Pharmaceut Co Ltd | Antiandrogen agent |
JP4585073B2 (en) * | 2000-02-15 | 2010-11-24 | 丸善製薬株式会社 | Anti-androgen, hair nourishing cosmetics, prostate hypertrophy inhibitor, external preparation and food and drink |
JP2002020242A (en) * | 2000-07-06 | 2002-01-23 | Lion Corp | Hair care preparation composition |
JP4627107B2 (en) * | 2000-07-06 | 2011-02-09 | ライオン株式会社 | Hair preparation for external use |
JP2003081802A (en) * | 2001-09-14 | 2003-03-19 | Kose Corp | Masking agent and cosmetic comprising the same |
KR100521782B1 (en) * | 2002-07-23 | 2005-10-14 | 주식회사 내츄로바이오텍 | Composition containing extract derived from natural products that have growth-inhibition activity against dandruff causing microorganism |
KR100521783B1 (en) * | 2002-07-23 | 2005-10-14 | 주식회사 내츄로바이오텍 | Composition containing extract derived from natural products that have growth-inhibition activity against dandruff causing microorganism |
KR20040016546A (en) * | 2002-08-17 | 2004-02-25 | 고운맘 | How to prepare wormwood oil |
JP2005035903A (en) * | 2003-07-16 | 2005-02-10 | Lion Corp | Hair-restoring and growing agent composition |
JP2013530214A (en) * | 2010-07-01 | 2013-07-25 | ユン コ、ド | Method for producing composition for improving hair and scalp condition in which efficacy of blended aroma oil is enhanced |
JP2013028572A (en) * | 2011-07-29 | 2013-02-07 | Unitika Ltd | Sebum production inhibitor |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3177642B2 (en) | Antiandrogens | |
JPH08310923A (en) | Testosterone 5alpha-reductase inhibitor | |
JP3611128B2 (en) | Testosterone-5-α-reductase inhibitor | |
JP2003238379A (en) | Skin care preparation and hair cosmetic | |
KR100484236B1 (en) | Hair Growth Promoting Composition | |
EP0279010A2 (en) | 5-alpha-reductase inhibitor | |
JP4241958B2 (en) | Androgen receptor binding inhibitor | |
JP2001187742A (en) | Testosteron-5-alfa-reductase inhibitor | |
EP0028525A2 (en) | Hair treatment agent promoting the growth of hair and preventing dandruff | |
JP3553956B2 (en) | Blood flow improver and cosmetics | |
JP3568311B2 (en) | Hair restorer | |
JPS59172411A (en) | Hair tonic composition containing fatty acid | |
JPH07258063A (en) | External preparation for skin | |
JP3276327B2 (en) | Testosterone 5α-reductase inhibitor | |
JP2002284648A (en) | Composition for hair restorer | |
JP2011219462A (en) | Cosmetic or phamaceutical composition containing kuzu flower extract | |
JP2753607B2 (en) | Testosterone 5α-reductase inhibitor | |
JP4455682B2 (en) | Testosterone 5α-reductase inhibitor | |
KR20080011970A (en) | Compositions for prevention of hair loss or hair restoration containing extracts of pueraria plants | |
JPH1179948A (en) | Hair tonic and hair cosmetic, and preparation for external use for skin for suppressing sebum secretion | |
JP3165832B2 (en) | Antiandrogens | |
JP2001302528A (en) | TESTOSTERONE 5alpha-REDUCTASE INHIBITOR, AGENT FOR HAIR AND SKIN COSMETIC | |
JP2019206490A (en) | Mixed component having 5α-reductase inhibitory action, and composition for hair growth containing the same | |
JPH04356416A (en) | Skin cosmetic | |
WO2017099321A9 (en) | Cosmetic composition for suppressing sebum secretion containing prunus humilis bunge seed extract as active component |